Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics | DEF 14A: Definitive information statements
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | 8-K: Current report
Carisma Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Carisma Therapeutics | 8-K: Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
Carisma Therapeutics | DEF 14A: Definitive proxy statements
Carisma Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
No Data
No Data